BIO240517C380000
- 1.00
- 0.000.00%
Bio-Rad Laboratories Newsroom
Express News | Federal Register Reported FDA Announcing Revocation Of EUAs Issued To Bio-Rad Laboratories For The Bio-Rad Sars-Cov-2 DDPCR Kit
Express News | U.S. Federal Register: FDA Revoked Authorizations Under Federal Food, Drug, and Cosmetic Act as Requested by the Authorization Holders
Express News | U.S. Federal Register: FDA Announcing Revocation of Euas Issued to Fast Track Diagnostics Luxembourg S.á.r.l. for Ftd Sars-Cov-2
Express News | U.S. Federal Register: FDA Announcing Revocation of Euas Issued to Bio-Rad Laboratories for the Bio-Rad Sars-Cov-2 Ddpcr Kit
Bio-Rad Laboratories, Inc. (NYSE:BIO) Just Reported, And Analysts Assigned A US$394 Price Target
Last week saw the newest quarterly earnings release from Bio-Rad Laboratories, Inc. (NYSE:BIO), an important milestone in the company's journey to build a stronger business. The analysts typi
Bio-Rad Laboratories | 10-Q: Quarterly report
The Analyst Landscape: 4 Takes On Bio-Rad Laboratories
Bio-Rad Laboratories (NYSE:BIO) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.The following table summarizes their recent
UBS Adjusts Price Target on Bio-Rad Laboratories to $385 From $420, Maintains Buy Rating
Bio-Rad Laboratories (BIO) has an average outperform rating and price target range of $365 to $441, according to analysts polled by Capital IQ. Price: 271.46, Change: -8.45, Percent Change: -3.02
Express News | Bio Rad Laboratories Inc : UBS Cuts Target Price to $385 From $420
Bio-Rad Laboratories Is Maintained at Buy by UBS
Bio-Rad Laboratories Is Maintained at Buy by UBS
Bio-Rad Laboratories Price Target Cut to $385.00/Share From $420.00 by UBS
Bio-Rad Laboratories Price Target Cut to $385.00/Share From $420.00 by UBS
Express News | UBS Maintains Buy on Bio-Rad Laboratories, Lowers Price Target to $385
Bio-Rad Laboratories Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/08/2024 38.34% UBS $420 → $385 Maintains Buy 04/03/2024 31.15% Citigroup $400 → $365 Downgrades Buy → N
RBC Adjusts Price Target on Bio-Rad Laboratories to $414 From $420
Bio-Rad Laboratories (BIO) has an average outperform rating and a price target range of $365 to $441, according to analysts polled by Capital IQ. Price: 277.00, Change: -2.91, Percent Change: -1.04
Citigroup Adjusts Price Target on Bio-Rad Laboratories to $300 From $365
07:37 AM EDT, 05/08/2024 (MT Newswires) -- Citigroup Adjusts Price Target on Bio-Rad Laboratories to $300 From $365 Price: 279.11, Change: -0.80, Percent Change: -0.29
Analysts Are Bullish on These Healthcare Stocks: Bio-Rad Laboratories (BIO), Caribou Biosciences (CRBU)
Express News | Bio Rad Laboratories Inc : Citigroup Cuts Target Price to $300 From $365
Earnings Call Summary | Bio-Rad Laboratories(BIO.US) Q1 2024 Earnings Conference
The following is a summary of the Bio-Rad Laboratories, Inc. (BIO) Q1 2024 Earnings Call Transcript:Financial Performance:Bio-Rad reported a decrease in Q1 2024 net sales to $611 million, largely due
Research Alert: CFRA Retains Hold Opinion On Shares Of Bio-rad Laboratories, Inc.
CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We cut our target to $290 from $360, 24.
Bio-Rad Laboratories Inc (BIO) Q1 2024 Earnings: Mixed Results Amid Market Challenges